SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 9, 2001
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
PAGE 1 OF 4 PAGES.
Item 5. OTHER EVENTS
On October 9, 2001, Genome Therapeutics Corp. issued a press release
announcing that it has acquired the exclusive license in the United States and
Canada for the novel antibiotic, Ramoplanin, from Biosearch Italia S.p.A. (Nuovo
Mercato: BIO.MI), a leading Italian biotechnology company focused on new
antibiotics for treating infectious diseases caused by multi-resistant
micro-organisms (bacteria and fungi). A copy of this press release is attached
to this Current Report on Form 8-K as Exhibit 99.1.
PAGE 2 OF 4 PAGES.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Stephen Cohen
-------------------------------
Name: Stephen Cohen
Title: Chief Financial Officer
Date: October 9, 2001
PAGE 3 OF 4 PAGES.
EXHIBIT INDEX
99.1 Press Release dated October 9, 2001
PAGE 4 OF 4 PAGES.